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INTRODUCTION
To compact DNA, chromatin is wrapped
tightly around nuclear histones, which are
maintained in a state of deacetylation by
histone deacetylases (HDAC). Histone
acetylases, on the other hand, hyperacety-
late histones, which then unravel DNA
and permit transcription factors to bind
and initiate gene expression. In humans,
there are 18 distinct HDAC divided into
three classes based on their dependence
on zinc for enzymatic activity (1). In addi-
tion to their ability to deacetylate the
highly conserved N-terminal lysines pres-
ent on histones, other functions of each
HDAC, such as acetylation of cytoplasmic
proteins, also may contribute to their ef-
fects on cellular functions.
Inhibitors of HDAC are used widely in
medicine. Valproic acid, the drug of choice
for chronic therapy of generalized and
focal epilepsy as well as obsessive disor-
ders (2) is an HDAC inhibitor (3). Valproic
acid also has been tested in patients with
HIV-1 to purge the latently infected pool
of memory T-cells (4). The HDAC in-
hibitor sodium butyrate is used to treat
patients with sickle cell anemia and 
β-thalassemia (5,6). More potent synthetic
inhibitors of HDAC also have been devel-
oped as a therapy in cancer (7). At micro-
molar concentrations, synthetic inhibitors
of HDAC increase the expression of sev-
eral proapoptotic genes that often are si-
lenced in malignant cells, thus driving the
cells toward an anticancerous phenotype.
The hydroxamic acid–containing HDAC
inhibitor suberoylanilide hydroxamic acid
(SAHA) (7–10) has been approved for the
treatment of cutaneous T-cell leukemia
(11) and appears to benefit patients with
acute myeloid leukemia (12). However,
SAHA also exhibits immunosuppressive
and antiinflammatory  properties (13).
ITF2357 is a novel hydroxamic
acid–containing, orally active HDAC in-
hibitor that targets Class I and II HDAC.
ITF2357 is effective as an antiinflamma-
tory agent in animal models of inflam-
matory and autoimmune diseases
(13–20). In vitro, the antiinflammatory
properties of ITF2357 reduce production
and/or activities of proinflammatory
cytokines and are observed consistently
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In type 1 diabetes, inflammatory and immunocompetent cells enter the islet and produce proinflammatory cytokines such as
interleukin-1β (IL-1β), IL-12, tumor necrosis factor-α (TNFα) and interferon-γ (IFNγ); each contribute to β-cell destruction, mediated
in part by nitric oxide. Inhibitors of histone deacetylases (HDAC) are used commonly in humans but also possess antiinflammatory
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creased in association with reduced islet-derived nitrite levels. In peritoneal macrophages and splenocytes, ITF2357 inhibited the
production of nitrite, as well as that of TNFα and IFNγ at an IC50 of 25–50 nmol/L. In the insulin-producing INS cells challenged with
the combination of IL-1β plus IFNγ, apoptosis was reduced by 50% (P < 0.01). Thus at clinically relevant doses, the orally active
HDAC inhibitor ITF2357 favors β-cell survival during inflammatory conditions.
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in the low nanomolar range. As an
 antiinflammatory agent and cytokine-
suppressing molecule, ITF2357 is 
25–50-fold more effective than SAHA in
vivo and in vitro (13,14,17,20–22). In en-
dotoxin-stimulated human peripheral
blood mononuclear cells (PBMC),
ITF2357 inhibited the release of TNFα
and IL-1β by more than 50% at 12.5 to
25 nmol/L, respectively (17). The induc-
tion of IFNγ by the combination of IL-18
plus IL-12 also was reduced by ITF2357.
These data are consistent with the abil-
ity of nanomolar concentrations of
ITF2357 to inhibit the enzymatic activity
of Class I HDAC (23).
Safe and specific antiinflammatory
agents are sought for the prevention of
 cytokine-induced destruction of pancreatic
islet β cells. Oral ITF2357 is safe and effec-
tive in humans and is being evaluated
presently in adults and children. In a
Phase II study, ITF2357 reduced the consti-
tutive proliferation of hematopoietic cells
from patients with myeloproliferative neo-
plasms (24). In children with active sys-
temic onset juvenile idiopathic arthritis, a
daily oral dose of ITF2357 at 1.5 mg/kg
for 12 weeks exhibited no organ toxicity
and achieved significant reduction in pa-
rameters of systemic disease as well as the
number of painful joints (25).
Since targeting IL-1β-mediated in-
flammation to protect islets has been
demonstrated in human trials (26,27),
the use of oral HDAC inhibitors to tar-
get islet inflammation should be con-
sidered. In vitro HDAC inhibitors re-
duced cytokine-induced nitric oxide
formation (as measured by nitrite lev-
els) in macrophages (13) and the de-
cline in insulin secretion in isolated rat
islets (28–30). In the present report, we
describe the ameliorating properties of
low doses of ITF2357 administered
orally to mice in protecting islets ex-
posed to inflammatory challenges as
well as the reduction of cytokine pro-
duction and increased β-cell survival.
These studies suggest that oral ITF2357
would be a safe and possibly effective
candidate for reducing inflammation in
the islets in type 1 diabetes.
MATERIALS AND METHODS
Reagents
Recombinant mouse IL-1β, IL-12,
TNFα and IFNγ were obtained from Pe-
protech (Rocky Hill, NJ, USA) and BD
Pharmingen (Erembodegen, Belgium).
Mouse IL-18 was from R&D Systems
(Oxon, UK). Recombinant rat IFNγ was
obtained from R&D Systems. ITF2357
was synthesized as described previously
(17), reconstituted in water to 1 mg/mL,
heated to 80°C and kept at room temper-
ature. ITF2357 is stable at room tempera-
ture for 2 years. Streptozotocin (STZ)
was purchased from Sigma, St. Louis,
MO, USA.
Animals
Six- to 7-wk-old C57BL/6 female mice
were purchased from Jackson Laborato-
ries (Bar Harbor, ME). Three- to 6-day-
old Wistar Furth rats were purchased
from Charles River Laboratories
(Sulzfeld, Germany). In vivo experiments
were approved by the University of Col-
orado Institutional Animal Care and Use
Committee.
In Vivo STZ Model
STZ was reconstituted in cold sodium-
citrate buffer pH 4.3 immediately before
use. Mice were injected intraperitoneally
(i.p.) with STZ (225 mg/kg). ITF2357
(1.25, 2.5 and 5 mg/kg) or water (vehi-
cle) was administered by gavage 
(0.1 mL), 12 h and 4 h prior to STZ, and
every 12 h thereafter. Forty-eight h after
STZ injection, β-cell function was as-
sessed by glucose challenge and serum
was collected for nitrite levels, as de-
scribed below.
Glucose Tolerance Test (GTT) and
Glucose Clearance in Mice
Mice were challenged after an
overnight fast with glucose (2 mg/g), as
described elsewhere (31). Blood glucose
was measured prior to injection, and
then at 10, 30, 60 and 90 min after chal-
lenge. Glucose clearance was calculated
as percent of glucose that was removed
from circulation 60 min after challenge.
Mouse Islets
Mice were anesthetized and pancreata
were inflated with collagenase (1 mg/mL,
type XI, Sigma), excised and incubated
for 40 min at 37°C. Digested pancreata
were vortexed gently, filtered through a
500-micron sieve and the pellet washed
in HBSS containing 0.5% BSA (Sigma).
The pellet was resuspended in RPMI
1640 supplemented with 10% FCS, 
50 IU/mL penicillin and 50 μg/mL strep-
tomycin (Cellgro, Herndon, VA, USA).
Islets were collected on 100-micron cell
strainer (BD Falcon, Franklin Lakes, NJ,
USA) and handpicked under a micro-
scope. Immediately after collection, islets
were incubated at 37ºC for 24 h before in
vitro assays. 100 islets per well were
seeded in a 48-well plate. Islet viability
was assessed using an MTT-based assay
(Sigma).
Mouse Peritoneal Macrophages and
Splenocytes
Thioglycollate-elicited mouse peri-
toneal macrophages and splenocytes
were isolated as described elsewhere (32).
Splenocytes were cultured in 96-well
plates at 0.5×106 per well in triplicate.
Rat Islets
Primary neonatal rat islets were iso-
lated and precultured for 1 wk as de-
scribed previously (28) in complete me-
dium (RPMI 1640 with 100 IU/mL
penicillin and 100 μg/mL streptomycin)
and supplemented with 10% newborn
calf serum (Invitrogen/Gibco, Taastrup,
Denmark). Five-hundred randomly
picked islets per mL of complete me-
dium containing 0.5% pooled human
serum or 50 islets per 100 μL complete
medium plus 0.5 % human serum were
transferred to 12-well or 96-well plates
(Nunc, Roskilde, Denmark), respectively.
Islets were exposed to ITF2357 or vehicle
for 1 h and, subsequently, cytokines were
added.
Cytokine Assays
Murine IFNγ was determined using
specific enzyme-linked immunosorbent
assay (ELISA) (R&D Systems) given
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above. Murine TNFα, macrophage in-
flammatory protein 1α (MIP-1α) and
MIP-2 were detected by electrochemilu-
minescence (ECL) assay as described
previously (33,34). The amount of chemi-
luminescence was determined using an
Origen Analyzer (BioVeris, Gaithersburg,
MD, USA).
Immunoblotting
Five-hundred randomly picked islets
were cultured for 2–3 h and pre-exposed
to ITF2357 or vehicle for 1 h. IL-1β
(160 pg/mL) plus IFNγ (5 ng/mL) was
added for 6 h and islets were then lysed
and the protein content measured by the
Bradford method. Lysates were sub-
jected to gel electrophoresis as described
(35). Anti-iNOS antibody (#610332) was
purchased from BD Pharmingen (San
Diego, CA, USA), anti–β-actin (ab6276)
was from Abcam (Cambridge, UK) and
antimouse was from Cell Signaling (Bev-
erly, MA, USA). Immune-complexes
were detected by chemiluminescence
using LumiGLO (Cell Signaling) and
light emission captured digitally by use
of the Fuji LAS3000 (Fujifilm, Tokyo,
Japan).
INS-1 Cells
INS-1 cells were a kind gift from C
Wollheim, Geneva (28) and were main-
tained in RPMI 1640 supplemented with
Glutamax, 10% fetal calf serum, 100 IU/mL
penicillin, 100 μg/mL streptomycin and
50 μmol/L 2-mercaptoethanol (Sigma).
Cells were cultured at 37°C, 5% CO2 and
subcultured weekly.
Nitrite Assay
Nitric oxide was determined by mea-
suring nitrite levels in sera and in islet
supernatants. Material was analyzed for
accumulated nitrite using Griess reagent
(Promega, Madison, WI, USA).
Mitochondrial Activity Assay
Cells were cultured as described for
insulin assay. Following cytokine expo-
sure, the proportion of metabolically
 active cells were determined by 3-(4,5-
dimethyldiazol-2-yl)-2,5-diphenyl-
 tetrazolium bromide (MTT) assay
(Promega, Madison, WI, USA).
TUNEL Assay
Three-hundred thousand INS-1 cells
were cultured in 2-well chamber slides
(Nunc) in 1.5 mL complete medium and
exposed to IL-1β (250 pg/mL) and IFNγ
(10 ng/mL) for 24 h. The terminal deoxy -
nucleotidyl transferase mediated dUTP
nick end labeling (TUNEL) assay was per-
formed according to manufacturer instruc-
tions (Chemicon Europe, Hampshire, UK).
Subsequently, cells were stained with
DAPI nuclear stain (1 μg/mL, Merck) for
30 min at room temperature, rinsed in PBS
and the slides mounted using drops of
Antifade Mounting Media (No. 002627;
Dako, Carpintaria, CA, USA).
Morphological Analysis
Three-hundred thousand INS-1 cells
were cultured for 2 d prior to cytokine
treatment. On the day of the experi-
ment, the medium was replaced and
ITF2357 was added 30 min preceding
the addition of IL-1β (250 pg/mL) and
IFNγ (10 ng/mL). After 24 h at 37°C, the
cells were rinsed in PBS, fixed in 1%
paraformaldehyde overnight at 4°C and
incubated with DAPI stain.
Statistics
The data are presented as mean ± SEM
of independent experiments. Paired Stu-
dent t test was used to analyze statistical
significance.
RESULTS
ITF2357 Prevents the Onset of
Hyperglycemia and Decreases
Serum Nitrite Levels in a Mouse Model
of STZ-Induced β-Cell Toxicity
C57BL/6 mice received an oral dose
of 1.25, 2.5 or 5.0 mg/kg ITF2357 or
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Figure 1. Effects of oral ITF2357 on STZ-induced β-cell toxicity, serum nitric oxide levels and
spleen cell responses in vivo. C57BL/6 mice received either 100 μL vehicle (water) or ITF2357
per os at indicated doses, 12 and 24 h before a single STZ injection (225 mg/kg, i.p.). Mice
that did not receive STZ represent the nondiabetic (non-DB) group. ITF2357 and vehicle
treatment were repeated 12, 24 and 36 h after STZ (n = 5 per treatment group). (A–C) β-cell
function was evaluated 48 h after STZ injection. (A) Fasting glucose levels. Percentiles ± SEM,
*P < 0.05; (B) Glucose tolerance test (GTT), mean ± SEM; (C) glucose clearance. Percent-
age of decrease in blood glucose 30 min after peak GTT-induced circulating glucose lev-
els. Mean ± SEM, *P < 0.05. (D) Mean ± SEM serum nitric oxide levels, as determined by nitrite
levels. **P < 0.01. (E) Mean ± SEM TNFα levels in 24 h supernatants from ConA (1 μg/mL) stim-
ulated mouse spleen cells. Spleens were removed from mice 48 h after STZ. *P < 0.05.
water (0.1 mL, by gavage), 12 and 24 h
before a single injection of STZ 
(225 mg/kg, i.p.), and then again at 12,
24 and 36 h post-STZ. Forty-eight h
after STZ injection, glucose levels were
determined, glucose tolerance test
(GTT) was performed and serum col-
lected for nitrite levels. The spleens
were removed for ex vivo splenocyte
stimulation. As shown in Figure 1A, a
reduction of blood glucose was ob-
served with each of the three oral doses
of ITF2357, with an optimal response at
2.5 mg/kg (from 348 ± 64 mg/dL to 
120 ± 16 mg/dL, mean ± SE, P = 0.039).
Doubling of the dose of ITF2357 to 
5 mg/kg reduced glucose levels to 200
± 37 mg/dL.
As shown in Figure 1B, glucose chal-
lenge improved at the dose of 2.5 mg/kg
(P < 0.05), but was unaffected by either
lower or higher doses of ITF2357. As de-
picted in Figure 1C, blood glucose clear-
ance after a glucose challenge was maxi-
mal with an oral dose of 2.5 mg/kg 
(P < 0.05).
Serum nitrite levels were reduced 
in treated animals (Figure 1D), resulting
in a similar profile of inhibitory activity
as that observed in blood glucose levels
(Figure 1A). The dose of 2.5 mg/kg in-
hibited serum nitrite levels by 58.3 % 
(P < 0.005). The doses of 1.25 and 
5 mg/kg produced a nonsignificant 
reduction in nitrite levels. These data
are consistent with the findings pre-
sented in Figure 1A–C, confirming that
the optimal response to ITF2357 is ob-
tained at the intermediate dose of 
2.5 mg/kg.
To assess the effect of oral ITF2357 on
cellular responses attained at the tissue
levels of the inhibitor in vivo, spleno-
cytes were isolated from each of the
five mice that were not injected with
STZ (Figure 1D, non-DB). Cells were
cultured in the presence of ConA alone
(Figure 1E). Twenty-four h later, TNFα
levels were measured and revealed a
pattern consistent with the above obser-
vations, by which the optimal response
to ITF2357 is achieved at the dose of 
2.5 mg/kg.
ITF2357 Protects Mouse Islets from
 Cytokine-Induced Toxicity, Nitric
Oxide Generation and Chemokine
Production
Islets were isolated from C57BL/6
mice and were incubated in the presence
of the combination of IL-1β and IFNγ.
Cell viability was assessed and secreted
nitrite and chemokines were measured.
As shown in Figure 2A, after 48 h in the
presence of IL-1β and IFNγ, accumulated
nitrite levels reached 11.2 ± 0.8 μmol/L
(vehicle, set as 100%). Preincubation 
of islets with ITF2357 resulted in a
 concentration-dependent reduction in
nitrite levels. Fifty and 100 nmol/L
ITF2357 reduced nitrite levels by 41.6 ±
4% and 71.0 ± 12% (P < 0.05 and 0.01,
 respectively). At 200 nmol/L, ITF2357
reduced nitrite levels below detection.
Consistent with the marked decrease in
nitric oxide, cell viability was improved
(Figure 2B) and was three-fold greater at
200 nmol/L ITF2357 than in cytokine-
treated control islet cultures (P < 0.01).
As depicted in Figure 2C and D,
 cytokine-induced chemokine production
by cultured islets was inhibited by
ITF2357 in a concentration-dependent
manner. A 50% reduction in MIP-1α (Fig-
ure 2C) was observed at 50 nmol/L,
whereas a nearly 100% reduction was
achieved at 100 nmol/L ITF2357 (P <
0.001). At 200 nmol/L ITF2357, MIP-1α
levels were below constitutive MIP-1α
production levels (P < 0.001). Another
CXC chemokine, MIP-2, was reduced by
50% at 50 nmol/L ITF2357 (Figure 2D),
and was inhibited maximally at
200 nmol/L ITF2357 (P < 0.001).  Cytokine-
 induced apoptosis was determined in
mouse islets with the combination of IL-12
plus IL-18 added 1 h after pretreatment
with ITF2357. The average apoptotic rate
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Figure 2. ITF2357 protects from cytokine-induced islet injury in vitro. Primary mouse islets
were incubated for 1 h with increasing concentrations of ITF2357 or vehicle (water) and
then IL-1β (10 ng/mL) plus IFNγ (25 ng/mL) were added. The data are derived from three
independent experiments. Control (CT) islets were cultured without added cytokines.
After 48 h, cell viability, supernatant nitric oxide and chemokine levels were measured
and apoptosis rates were determined. Data from cytokine-stimulated islet cultures were
set at 100% and the percent change was calculated for each concentration of ITF2357.
(A) Mean ± SEM percent change in nitric oxide. (B) Cell viability, as determined by MTT re-
action, depicted as fold-change from CT. (C and D) Mean ± SEM percent change in
MIP-1α and MIP-2. *P < 0.05, **P < 0.01, ***P < 0.005 compared with stimulated islets in the
presence of vehicle. (E) Apoptosis, as determined by sub-G1 population evaluation of 
PI-stained islet single-cell suspension. ITF2357 (100 nmol/L) in the presence of IL-12 (2 ng)
plus IL-18 (20 ng)/mL.
of islets 24 h after cytokine stimulation re-
turned to control levels in the presence of
100 nmol/L ITF2357 (Figure 2E).
ITF2357 Protects Rat Islets from
 Cytokine-Induced Toxicity and
Reduces iNOS Expression
Islets were preincubated with increas-
ing concentrations of ITF2357 and then
exposed to the combination of IL-1β plus
IFNγ. After 48 h, insulin levels in the su-
pernatants were measured and islet via-
bility was evaluated. The mean insulin
 release in control islets was 1027 ± 
83 nmol/L. Following cytokine exposure,
the mean level fell to 230 ± 25 nmol/L; for
each experiment, the level of cytokine-in-
duced suppression of insulin was set at
100% (Figure 3A). The percent change
due to ITF2357 was determined for each
experiment and the mean values were cal-
culated. ITF2357 reversed the cytokine-
driven reduction of accumulated insulin
in a concentration-dependent manner. At
100 nmol/L, ITF2357 resulted in 50% less
cytokine- mediated suppression of insulin
release and, at 500 nmol/L, the HDAC in-
hibitor allowed for near-normal insulin
secretion (781 ± 90 nmol/L). Similarly, as
shown in Figure 3B, loss of islet viability
in the presence of IL-1β plus IFNγ, as as-
sessed by the MTT assay, was reduced at
200 nmol/L (45%, P < 0.001) and absent
at 500 nmol/L of ITF2357. In addtion, 
500 nmol/L of ITF2357 reduced cytokine-
induced apoptosis by 75% (P < 0.01) (Fig-
ure 3C). Finally, the combination of IL-1β
and IFNγ induced iNOS production in rat
islet cells (Figure 3D). As depicted by West-
ern blot analysis, there was a progressive
reduction in iNOS protein levels in the
presence of 100 to 500 nmol/L ITF2357.
ITF2357 Prevents Cytokine-Induced
Cell Death in Insulin-Secreting Rat 
INS-1 Cells
INS-1 cells were preincubated with
ITF2357 (250 nmol/L) and exposed to the
combination of IL-1β and IFNγ. Cytokine
stimulation for 24 h induced a profound
reduction in cell density (Figure 4A,
upper right panel), an effect that was ab-
rogated by ITF2357 (lower right panel).
Notably, cell population density in cy-
tokine-stimulated, ITF2357-treated cells
(lower right panel) was greater than in
nonstimulated cells (upper left panel),
suggesting that ITF2357 also prevents
spontaneous apoptosis that is related to
endogenous β-cell–derived injurious cy-
tokines under routine culture conditions.
In support of this concept, ITF2357 ap-
peared to increase cell density in un-
treated control cells (upper left versus
lower left panels). As shown in Figure 4B,
cytokine-induced apoptosis in INS-1 cells
as assessed by the TUNEL assay was re-
duced by ITF2357. At the lowest concen-
tration tested (62.5 nmol/L), apoptosis
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Figure 3. Effect of HDAC inhibition on insulin secretion, apoptosis, viability and iNOS expres-
sion in rat islets. Rat islets were precultured with increasing concentrations of ITF2357 for 1 h
and then IL-1β (160 pg/mL) and IFNγ (5 ng/mL) were added and the islets were cultured
for 48 h. The data are derived from 4–11 independent experiments. (A) Mean ± SEM per-
cent change in supernatant insulin levels. *P < 0.05, ***P < 0.001, t-test. (B) Mean ± SEM per-
cent change in islet viability by MTT. ***P < 0.001, t-test. (C) Mean ± SEM percent change in
islet apoptosis as assessed by the TUNEL assay (n = 4 **P < 0.01). (D) iNOS expression. West-
ern blot analysis of 6 h lysates. Actin control is shown. One blot representative of four.
Figure 4. Effect of HDAC inhibition on
 cytokine-induced INS-1 cell death. INS-1
cells were precultured with vehicle or
ITF2357 (250 nmol/L) and IL-1β (150 pg/mL)
and IFNγ (2 ng/mL) were then added for
24 h. CT, unstimulated cells. (A) DAPI stain-
ing of cell nuclei. (B) Cytokine-induced
apoptosis, assessed by the TUNEL assay.
Mean ± SEM, percent change set at 100%
for  cytokine-induced apoptosis, n = 4. **P <
0.01, ***P < 0.001.
was reduced by 35% (P < 0.01). Maximal
protection from apoptosis was obtained at 
250 nmol/L ITF2357 (P < 0.001).
ITF2357 Reduces Proinflammatory
Cytokine and Nitric Oxide Production
in Mouse Peritoneal Macrophages
Peritoneal macrophages were exposed to
ITF2357 1 h before addition of the combi-
nation of IL-18/IL-12 or TNFα/IFNγ. As
depicted in Figure 5A and B, production of
nitrite by peritoneal macrophages was re-
duced in a concentration- dependent man-
ner. IFNγ induction of TNFα (Figure 5C)
was similarly reduced by ITF2357, and, at
a concentration as low as 25 nmol/L, was
reduced by 50%. At 50 nmol/L ITF2357,
TNFα production was nearly completely
abolished. Similarly, TNFα induction of
IFNγ (Figure 5D) exhibited an 86% reduc-
tion at 100 nmol/L ITF2357.
ITF2357 Reduces Proinflammatory
Cytokine Production in Cultured
Mouse Splenocytes
The effects of ITF2357 were also assessed
in ConA-stimulated mouse splenocytes.
Basal levels of TNFα and IFNγ were 11 and
30 pg/mL and increased to 556 ± 132 and
1230 ± 460 pg/mL following exposure to
the stimulant. As shown in  Figure 6,
ConA-induced IFNγ and TNFα produc-
tions were reduced in mouse splenocytes
in a concentration-dependent manner.
IFNγ was reduced to 50% at 12.5 nmol/L
ITF2357 and TNFα was reduced to 50% at
50–100 nmol/L ITF2357 (P < 0.05).
DISCUSSION
We began these studies with oral dos-
ing of ITF2357 in mice and observed a
significant reduction in the development
of hyperglycemia induced by a single
administration of STZ. In this acute
model, circulating nitrite levels increase
and there is death of the β cell. We ob-
served that the optimal efficacy of
ITF2357 in protecting islets from STZ
challenge was at 1.25 and 2.5 mg/kg. Al-
though the single dose STZ model is
clearly not a model for cytokine-
 mediated loss of the β-cell function in
type 1 diabetes, the rationale for using
this model was based on our earlier
studies demonstrating that SAHA inhib-
ited the production of nitrite from mouse
macrophages stimulated by IL-1β (13). In
the present studies, we used the single
dose STZ model to establish the dose of
oral ITF2357 to inhibit nitrite production
in a whole animal model. The dose of
1.25–2.5 mg/kg was optimal and consis-
tent with blood levels; these levels were
comparable to the nanomolar concentra-
tions of ITF2357 in vitro that protect
β cells. In a Phase I pharmacokinetic trial
in healthy humans, the mean maximal
plasma concentration was 104 nmol/L
2 h after a single oral dose of 50 mg;
after 100mg, the level was 199 nmol/L
(36). In those studies, the production of
IL-1β, TNFα and IFNγ was reduced sig-
nificantly in cultures of whole blood from
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Figure 5. Effect of ITF2357 on cytokine and NO production in peritoneal macrophages.
Thioglycollate-elicited mouse peritoneal macrophages were cultured in the presence of
increasing concentrations of ITF2357 1 h before the addition of cytokines as indicated
under the horizontal axes. After 48 h, levels of nitrite and released cytokines were deter-
mined in the supernatants. (A) Nitric oxide (as determined by nitrite) induced by TNFα
and IFNγ, (B) Nitric oxide (nitrite) induced by IL-12 and IL-18, (C) TNFα induced by IFNγ and
(C) IFNγ induced by TNFα. The data are expressed as the mean ± SEM percent change in
the absence of ITF2357. The data represent macrophage cultures from five separate mice
assayed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.005 compared with stimulated cells with-
out ITF2357.
Figure 6. Effect of ITF2357 on cytokine pro-
duction by mouse splenocytes. Mean ±
SEM percent change of TNFα and IFNγ
from mouse splenocytes. Splenocytes
were cultured in triplicate in round bot-
tom 96-well plates in the presence of
ITF2357 present for 1 h before the addition
of ConA (1 μg/mL). After 24 h, super-
natants were collected and cytokine lev-
els determined. Data are the combined
results from five spleens. *P < 0.05; **P <
0.01; ***P < 0.001.
the subjects (36). Thus, the effective oral
doses of ITF2357 in mice in the STZ
model are consistent with the blood lev-
els obtained in humans and also consis-
tent with the effective concentrations of
ITF2357 in vitro on mouse and rat islets
as well as on primary spleen and peri-
toneal cells in the present studies. Once
oral dosing was established, the study
focused on in vitro effects of ITF2357 rel-
evant to β-cell loss.
The antiinflammatory effects of oral
ITF2357 have been studied in children.
Seventeen children with active systemic
onset juvenile idiopathic arthritis were
treated for 12 weeks with a daily dose of
1.5 mg/kg of ITF2357. ITF2357 was safe
and after 12 weeks of daily dosing, there
was a 70% improvement in the juvenile
idiopathic arthritis score in 63% of pa-
tients, providing the proof-of-concept
that oral ITF2357 is a safe candidate for
treating inflammation (25). The observa-
tions of oral ITF2357 in healthy humans
and in children with arthritis are consis-
tent with the present studies in that low
concentrations of ITF2357 are antiinflam-
matory and protect the islet β cells.
In vitro, ITF2357 suppressed the β-cell
toxic effects of the combination of IL-1β
and IFNγ as well as reduced production
of islet-derived TNFα, IFNγ and nitrite.
Whereas gene expression and synthesis
of TNFα and IFNγ are effectively sup-
pressed by ITF2357 and SAHA in LPS-
stimulated human monocytes, gene ex-
pression of IL-1β and biosynthesis of
the IL-1β precursor are not affected
(13,17). Rather the effect of ITF2357 or
SAHA is primarily to reduce the secre-
tion of IL-1β. In fact, after reaching an
optimal suppression of IL-1β release, the
inhibitory activity of SAHA is dimin-
ished (13), and we have observed a sim-
ilar effect on IL-1β secretion by ITF2357.
Thus, the efficacy of protecting islets fol-
lowing STZ using 1.25 and 2.5 mg/kg
ITF2357, rather than 5 mg/kg, may re-
flect, in part, what the optimal dose is
for inhibiting the secretion of IL-1β.
There is a protective effect of specific 
IL-1 blockade in multiple low-dose STZ-
induced diabetes (37). Although we did
not use multiple low-dose STZ, we be-
lieve that inhibition of IL-1β may be
part of the protective mechanism of
ITF2357 in the single dose STZ model.
The optimal in vivo dose of 2.5 mg/kg is
consistent with the dose-response of
ITF2357 in inhibiting IL-1β secretion in
human PBMC (17) and consistent with
the blood levels achieved with ITF2357
in humans. The inhibitory effects of
ITF2357 on IL-1β secretion may involve
tubulin hyperacetylation; ITF2357 and
SAHA hyperacetylate HDAC-6, which
participates in tubulin assembly. Hyper-
acetylation of tubulin by HDAC in-
hibitors may therefore interfere with the
secretion of IL-1β by affecting the re-
lease of processed IL-1β via the secre-
tory lysosome (21).
In isolated rat islets, ITF2357 pre-
vented IL-1β/IFNγ-induced suppression
of insulin production, cell death and
iNOS expression. ITF2357 also afforded
protection against cytokine-induced apo-
ptosis in the rat clonal β-cell line, INS-1.
Moreover, in the absence of IL-1β/IFNγ,
control INS-1 cells exposed to ITF2357
(see Figure 4A, lower left) exhibited
higher cell density than cells without
ITF2357. This unexpected finding sug-
gests that there is intrinsic cell death in
INS-1 cells during standard incubation
conditions which may be similar to the
loss of β-cell function observed in patho-
logical conditions (38) and which is re-
duced by HDAC inhibition. It remains
unclear why ITF2357 appears to protect
β cells from intrinsic cell death, but simi-
lar protection was observed in vitro using
SAHA (28) and TSA (29). However, un-
like TSA, ITF2357 is orally active and
compared with SAHA provides longer
hyperacetylation of histones in primary
cells (17).
There was modest inhibition of
 cytokine-induced iNOS protein in rat
islets at 200 nmol/L ITF2357, but com-
plete inhibition of nitrite was observed in
mouse islets at this concentration. Adult
mouse islets are less sensitive to cytokine-
mediated death than neonatal rat islets
(28,39). Within but not between species,
there is consistent dose-dependent reduc-
tion in nitric oxide (NO) by HDAC inhi-
bition (see Figures 2A and 5) (28,30).
In diabetes, islets are assaulted initially
by infiltrating immune cells with the
subsequent development of insulitis. As
shown in Figure 2C and D, the combina-
tion of IL-1β and IFNγ induced the
chemokines MIP-1α and MIP-2, both
promoting the recruitment of
macrophages. In addition, these
chemokines induce the generation of re-
active oxygen species (40). Disruption of
this inflammatory cascade, such as that
which occurs in MIP-1α knockout mice
(41), results in reduced insulitis and pro-
tection from diabetes. In a recent report,
ITF2357 decreased surface expression of
the chemokine receptors CXCR4 and
CCR5 on CD4+ T-cells and monocytes
from healthy humans (23). Similar to re-
ducing the production of chemokines in
mouse islets, clinically achievable
nanomolar concentrations of ITF2357
suppress constitutive expression of the
receptors to these chemokines, and hence
would be an additional mechanism for
HDAC inhibition of insulitis.
There is clearly more than one mecha-
nism for the reduction in inflammation
by HDAC inhibitors relevant to type 1
diabetes. In humans, the expression of
the stimulatory CD154 molecule on
T cells from patients with various auto-
immune diseases has been reported (re-
viewed in [42]) and HDAC inhibitors
 reduce both CD154 and CD40 expression
on effector T cells (43). Inhibition of den-
dritic cell (DC) function is another prop-
erty of HDAC inhibitors. Pretreatment of
DC with ITF2357 significantly decreased
Toll-like receptor–induced secretion of
proinflammatory cytokines, suppressed
CD40 and CD80 expression and reduced
the in vitro and in vivo allostimulatory re-
sponses induced by the DC (44). In addi-
tion, injection of DCs treated ex vivo with
ITF2357 inhibited graft versus host dis-
ease (GVHD) during murine allogeneic
bone marrow transplantation (44). In-
creased expression of indoleamine 2,3-
dioxygenase, a known suppressor of DC
function, appears to be a property of
ITF2357 (44). Acetylation of the nonhis-
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tone protein signal transducer and
 activator-3 (STAT-3) by ITF2357 impli-
cates another mechanism for ITF2357
regulation of DC functions (45).
The suppression of IL-1β/IFNγ-driven
iNOS expression and NO production by
ITF2357 protected mouse and rat islet 
β cells as well as INS-1 cells from death.
Since IFNγ, an inducer of NO, also po-
tentiates the β-cell toxicity of IL-1β, inhi-
bition of IFNγ production (Figure 5D) is
highly relevant to islet survival. Both
IL-12 and IL-18 are required for the
 production of IFNγ and the combination
of IL-12 plus IL-18 induction of NO (Fig-
ure 5B) is likely mediated by IFNγ. At
100 nmol/L, ITF2357 inhibited the activity
of IL-12/IL-18 in human PBMC (17). In
the present studies, ITF2357 reduced
ConA-induced IFNγ in mouse splenocytes
as well as TNFα-induced IFNγ in peri-
toneal macrophages. The suppression of
IFNγ by ITF2357 may be due to reduced
IL-12. In fact, SAHA inhibits the produc-
tion of IL-12 in human blood monocytes
stimulated with LPS (13), an observation
confirmed in murine cells (46). IFNγ activ-
ity is dependent on STAT1. In a study of
GVHD, SAHA inhibited LPS-induced
phosphorylation of STAT1, which is es-
sential for IFNγ- induced NO (18). Inhibi-
tion of JAK kinases that phosphorylate
STAT-1 prevented NO production in LPS-
treated macrophages (18).
In islets, glucose stimulates IL-1β
 production (47,48); therefore, inhibition
of IL-1β secretion by HDAC inhibitors
may protect β cells from self-inflicted
damage driven by endogenous cytokines
during hyperglycemic states. As islet 
β-cell–derived cytokines contribute to the
progression of insulitis leading to dia-
betes, treatment with low doses of orally
active HDAC inhibitors, such as ITF2357,
provides an attractive approach for pro-
tecting the β cell. Thus, HDAC inhibitors
may serve as safe therapeutic target for
cytokine-mediated β-cell loss.
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